AnaptysBio, Inc. (ANAB) vs Intellia Therapeutics, Inc. (NTLA)
- AnaptysBio, Inc. ANAB 45.61 −0.26%
- Intellia Therapeutics, Inc. NTLA 9.78 −0.81%
AnaptysBio, Inc. and Intellia Therapeutics, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Intellia Therapeutics, Inc. are of similar size ($1.4B and $1.4B). Intellia Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. AnaptysBio, Inc. grew revenue faster over the last twelve months: 95.2% against −8.07%. AnaptysBio, Inc. has the higher net margin (6.54% vs −805.8%) and the higher return on invested capital (0.00% vs −195.3%). Across the 17 metrics below, AnaptysBio, Inc. leads on 14 and Intellia Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | ANAB | NTLA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | 36.14% | (821.24%) | 0.00% |
| Net margin | 6.54% | (805.75%) | 0.00% |
| Free cash flow margin | 0.00% | (671.57%) | 0.00% |
| Return on equity | (365.73%) | (62.60%) | (50.72%) |
| Return on assets | 4.76% | (46.63%) | (45.56%) |
| Return on invested capital | 0.00% | (195.32%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack